Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283520919> ?p ?o ?g. }
- W4283520919 endingPage "7051" @default.
- W4283520919 startingPage "7051" @default.
- W4283520919 abstract "Glioblastoma is the most malignant primary brain tumor, and a cornerstone in its treatment is radiotherapy. However, tumor cells surviving after irradiation indicates treatment failure; therefore, better understanding of the mechanisms regulating radiotherapy response is of utmost importance. In this study, we generated clinically relevant irradiation-exposed models by applying fractionated radiotherapy over a long time and selecting irradiation-survivor (IR-Surv) glioblastoma cells. We examined the transcriptomic alterations, cell cycle and growth rate changes and responses to secondary radiotherapy and DNA damage response (DDR) modulators. Accordingly, IR-Surv cells exhibited slower growth and partly retained their ability to resist secondary irradiation. Concomitantly, IR-Surv cells upregulated the expression of DDR-related genes, such as CHK1, ATM, ATR, and MGMT, and had better DNA repair capacity. IR-Surv cells displayed downregulation of hypoxic signature and lower induction of hypoxia target genes, compared to naïve glioblastoma cells. Moreover, Chk1 inhibition alone or in combination with irradiation significantly reduced cell viability in both naïve and IR-Surv cells. However, IR-Surv cells’ response to Chk1 inhibition markedly decreased under hypoxic conditions. Taken together, we demonstrate the utility of combining DDR inhibitors and irradiation as a successful approach for both naïve and IR-Surv glioblastoma cells as long as cells are refrained from hypoxic conditions." @default.
- W4283520919 created "2022-06-27" @default.
- W4283520919 creator A5010586477 @default.
- W4283520919 creator A5011855482 @default.
- W4283520919 creator A5013155674 @default.
- W4283520919 creator A5014100095 @default.
- W4283520919 creator A5022605436 @default.
- W4283520919 creator A5079606935 @default.
- W4283520919 creator A5084336730 @default.
- W4283520919 date "2022-06-24" @default.
- W4283520919 modified "2023-10-17" @default.
- W4283520919 title "Chronically Radiation-Exposed Survivor Glioblastoma Cells Display Poor Response to Chk1 Inhibition under Hypoxia" @default.
- W4283520919 cites W1967049179 @default.
- W4283520919 cites W1976096075 @default.
- W4283520919 cites W1982580926 @default.
- W4283520919 cites W2007109655 @default.
- W4283520919 cites W2007263630 @default.
- W4283520919 cites W2009215680 @default.
- W4283520919 cites W2012443680 @default.
- W4283520919 cites W2028035236 @default.
- W4283520919 cites W2038529685 @default.
- W4283520919 cites W2043536053 @default.
- W4283520919 cites W2047116883 @default.
- W4283520919 cites W2060551076 @default.
- W4283520919 cites W2070050178 @default.
- W4283520919 cites W2094665364 @default.
- W4283520919 cites W2096287682 @default.
- W4283520919 cites W2096460953 @default.
- W4283520919 cites W2099776053 @default.
- W4283520919 cites W2108791713 @default.
- W4283520919 cites W2112992354 @default.
- W4283520919 cites W2120918787 @default.
- W4283520919 cites W2121205576 @default.
- W4283520919 cites W2130351327 @default.
- W4283520919 cites W2132834292 @default.
- W4283520919 cites W2151252396 @default.
- W4283520919 cites W2157247642 @default.
- W4283520919 cites W2238041893 @default.
- W4283520919 cites W2345356016 @default.
- W4283520919 cites W2392045628 @default.
- W4283520919 cites W2473691951 @default.
- W4283520919 cites W2532525412 @default.
- W4283520919 cites W2549803280 @default.
- W4283520919 cites W2585659713 @default.
- W4283520919 cites W2586629973 @default.
- W4283520919 cites W2614456022 @default.
- W4283520919 cites W2623802897 @default.
- W4283520919 cites W2750357431 @default.
- W4283520919 cites W2753941672 @default.
- W4283520919 cites W2766300480 @default.
- W4283520919 cites W2766459017 @default.
- W4283520919 cites W2793317283 @default.
- W4283520919 cites W2799878046 @default.
- W4283520919 cites W2838310729 @default.
- W4283520919 cites W2898088739 @default.
- W4283520919 cites W2900254393 @default.
- W4283520919 cites W2913847887 @default.
- W4283520919 cites W2914382008 @default.
- W4283520919 cites W2918252715 @default.
- W4283520919 cites W2923094687 @default.
- W4283520919 cites W2947007067 @default.
- W4283520919 cites W2947916475 @default.
- W4283520919 cites W2950835872 @default.
- W4283520919 cites W2955294253 @default.
- W4283520919 cites W2992297284 @default.
- W4283520919 cites W3022486080 @default.
- W4283520919 cites W3028078525 @default.
- W4283520919 cites W3034609144 @default.
- W4283520919 cites W3081723185 @default.
- W4283520919 cites W3082792492 @default.
- W4283520919 cites W3103080601 @default.
- W4283520919 cites W3107353820 @default.
- W4283520919 cites W3111039608 @default.
- W4283520919 cites W3145969289 @default.
- W4283520919 cites W3165694693 @default.
- W4283520919 cites W3169314086 @default.
- W4283520919 cites W3195220703 @default.
- W4283520919 cites W3214021710 @default.
- W4283520919 cites W4206253471 @default.
- W4283520919 cites W4210363429 @default.
- W4283520919 cites W4225537034 @default.
- W4283520919 doi "https://doi.org/10.3390/ijms23137051" @default.
- W4283520919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35806055" @default.
- W4283520919 hasPublicationYear "2022" @default.
- W4283520919 type Work @default.
- W4283520919 citedByCount "2" @default.
- W4283520919 countsByYear W42835209192023 @default.
- W4283520919 crossrefType "journal-article" @default.
- W4283520919 hasAuthorship W4283520919A5010586477 @default.
- W4283520919 hasAuthorship W4283520919A5011855482 @default.
- W4283520919 hasAuthorship W4283520919A5013155674 @default.
- W4283520919 hasAuthorship W4283520919A5014100095 @default.
- W4283520919 hasAuthorship W4283520919A5022605436 @default.
- W4283520919 hasAuthorship W4283520919A5079606935 @default.
- W4283520919 hasAuthorship W4283520919A5084336730 @default.
- W4283520919 hasBestOaLocation W42835209191 @default.
- W4283520919 hasConcept C104317684 @default.
- W4283520919 hasConcept C126322002 @default.